Roy Bloom

Roy Bloom is a nephrologist associated with the University of Pennsylvania Medical Center in Philadelphia and a recurring contributor to the book’s clinical account of Hepatitis C in end-stage renal disease. His significance lies less in a personal narrative than in the practical framework his research supplies: HCV-infected kidney transplant candidates must be identified accurately, their liver disease must be staged before listing, and the apparent risks of transplantation must be weighed against the substantial danger of remaining on dialysis or waiting for an organ.

Identity and Professional Setting

Roy Bloom appears as a physician in the Division of Nephrology at the University of Pennsylvania Medical Center, Philadelphia, where he worked with David Roth on the selection and management of HCV-infected patients for the kidney transplant waiting list. He also appears with Jose M. Morales and David Roth as a contributor to the discussion of kidney transplantation in patients with HCV infection. These affiliations place him at the intersection of nephrology, hepatology, transplantation, and outcomes research rather than in a narrowly single-organ specialty.

His work is presented through collaborative clinical studies, reviews, and registry-informed interpretation. The book repeatedly associates Bloom with questions that have immediate consequences for eligibility and survival: which candidates have advanced liver injury, how HCV should be confirmed, whether a patient can safely remain listed for kidney-alone transplantation, and whether transplantation offers a survival advantage over continued dialysis. His role is therefore institutional and analytic, but the decisions under examination are intensely consequential for individual patients.

Research on Candidates Who Remain on the Waiting List

Bloom is a principal author of the study examining HCV-infected kidney transplant candidates who remain on the waiting list. That study is used to show that the waiting list is not a neutral holding area. Candidates may deteriorate while they wait, and the clinical status that initially made kidney-alone transplantation appropriate may change during a prolonged delay. In some areas of the United States, waiting times approach five to seven years, making continued surveillance an essential part of transplant management rather than an administrative formality.

One of Bloom’s most distinctive findings concerns diabetes mellitus. Among HCV-infected kidney candidates on the waiting list, diabetes was significantly more prevalent than in the comparison cohort. In a Cox regression model that included the usual clinical variables, diabetes was the only factor associated with increased risk of death, with a hazard ratio of 2.17 and a 95% confidence interval of 1.1–4.1. Liver disease itself was not predictive of mortality in that model. The finding redirects attention from a simple liver-centered account of HCV toward the broader metabolic and cardiovascular vulnerability of patients with chronic kidney disease.

That result also changes how the waiting list is interpreted. Death on the list was the primary reason HCV-infected patients were delisted in the reported study, whereas liver disease was a much less frequent cause. Bloom’s work consequently supports robust cardiovascular surveillance, especially because diabetes is common in this population and cardiovascular disease is the leading contributor to mortality among patients on United States kidney transplant waiting lists. The danger is not confined to eventual cirrhosis; it is also the immediate attrition of patients whose chances of transplantation decline while they remain under observation.

Screening, Staging, and Ongoing Eligibility

The transplant framework associated with Bloom begins with systematic detection. Candidates should be screened for anti-HCV antibody and, where appropriate, active viremia by nucleic acid testing. In lower-prevalence regions, a positive enzyme immunoassay result should be confirmed by nucleic acid testing; in higher-prevalence settings, direct nucleic acid testing is appropriate. Patients with a positive nucleic acid test should be placed on hold status and referred to a hepatologist for evaluation and possible treatment.

Bloom’s clinical position emphasizes that detecting viremia is only the beginning. Between 10% and 25% of pre-kidney-transplant candidates have advanced liver injury, including stage 3 or stage 4 disease, when evaluated by biopsy. Although noninvasive markers have been sought, liver biopsy remains the gold standard in the evidence presented. The KDIGO Workgroup therefore recommended percutaneous liver biopsy for all HCV-infected patients being considered for kidney transplantation, allowing clinicians to distinguish candidates suitable for kidney-alone transplantation from those whose liver disease requires a combined liver-kidney strategy.

The same logic extends through the waiting period. Patients who achieved a sustained virological response before transplantation should undergo nucleic acid testing at least annually to confirm that the response remains durable. Relapse should lead to hold status and hepatology referral for possible retreatment. Patients who remain viremic should receive annual assessment for progression of liver disease. In the cited experience, eight of thirteen patients, or 62%, whose repeat biopsies were obtained while they remained on the waiting list showed worsening liver histology. By contrast, only seven of thirty-one, or 23%, of follow-up biopsies obtained after transplantation showed interval worsening. The comparison gives the waiting period a measurable pathological cost.

The monitoring schedule is correspondingly stratified. Candidates with Metavir stage 1 or 2 fibrosis should have repeat biopsy every five years, while those with stage 3 fibrosis should be rebiopsied after three years. Progression to early or established cirrhosis should remove a patient from the kidney-only list and prompt referral to the liver transplant team for consideration of simultaneous liver-kidney transplantation. Bloom’s contribution thus converts a static eligibility decision into a sequence of reassessments governed by fibrosis stage, virologic status, and changing transplant risk.

Transplantation Versus Continued Dialysis

Bloom’s research is central to the book’s conclusion that HCV infection worsens outcomes but does not ordinarily negate the value of kidney transplantation. Several studies comparing HCV-infected patients who received a kidney transplant with those who remained on dialysis or on the waiting list found lower mortality after transplantation. Pereira and colleagues reported a relative risk of death of 0.31 during the seven- to forty-eight-month posttransplant period for transplanted HCV-positive patients compared with those remaining on the waiting list. Bloom’s own study likewise showed lower mortality among transplanted HCV-infected patients than among candidates who remained listed.

The timing of this benefit is not uniform. In a later analysis by Roth and collaborators of 175 listed candidates with documented HCV infection, the hazard ratio for death was 2.51 during the first six months after transplantation, but fell to 0.32 during months seven through eighty-four. The early period therefore carries substantial risk, while the subsequent years reveal the survival advantage of transplantation. Bloom’s work helps preserve both sides of that finding: transplantation is not immediately harmless, but remaining dependent on dialysis is not the safer long-term default.

This conclusion is especially important because HCV-positive transplant recipients have inferior survival compared with recipients without evidence of infection. A meta-analysis of eight clinical trials involving 6,365 patients found a relative risk of mortality of 1.79 associated with HCV infection, partly because of increased liver-related death. Yet the relevant clinical comparison is not only infected versus uninfected recipients. When the alternative is continued dialysis, transplantation remains the preferred renal replacement therapy for an HCV-infected patient who does not have advanced liver injury on pretransplant biopsy.

Graft Outcomes and Broader Significance

Bloom’s transplant work also belongs to a more difficult story about graft survival. In one comparison, 488 anti-HCV-positive recipients had a higher adjusted risk of graft loss than 2,877 seronegative recipients, with an adjusted relative risk of 1.53. In Australian and New Zealand registry data, five-year graft survival was worse in the anti-HCV-positive cohort, with an adjusted hazard ratio of 1.71 for graft failure. Graft loss was more often attributed to glomerulonephritis and chronic allograft nephropathy among HCV-positive recipients, even though other studies did not find a statistically significant increase.

The evidence associated with Bloom also complicates the assumption that every HCV-positive patient should be treated or excluded before transplantation. There is no consensus that active viremia must always be eradicated before transplant, and the benefits of pretransplant interferon therapy for graft and patient survival had not been proven. Treatment may reduce posttransplant HCV-related glomerulonephritis and chronic allograft nephropathy, but interferon carries adverse effects, has a substantial nonresponse rate, requires a prolonged course, can temporarily exclude patients from the waiting list, and is not universally affordable. Patients who cannot tolerate, decline, or fail therapy may still have a more favorable course with transplantation than with continued dialysis.

That reasoning opens onto the controversial use of kidneys from HCV-positive donors. Because transplantation can shorten waiting time and because many HCV RNA-positive candidates will not receive effective antiviral therapy, such kidneys may be offered to carefully selected HCV RNA-positive recipients who consent in advance. The policy does not eliminate transmission risk, and it should not be extended indiscriminately to recipients without active HCV infection. Nevertheless, the Spanish experience cited in the book found no difference in patient survival between HCV RNA-positive recipients receiving kidneys from HCV-positive donors and those receiving kidneys from HCV-negative donors over a mean follow-up of 74.5 months; donor HCV-positive serology was not an independent risk factor for death, graft loss, or progression to advanced liver disease.

Roy Bloom’s narrative role is therefore that of a clinician-researcher who resists one-dimensional risk labels. HCV positivity can signify increased mortality, metabolic vulnerability, liver progression, graft injury, or infection-related danger, but none of those meanings can be inferred safely from antibody status alone. His work insists on distinctions between antibody positivity and active viremia, fibrosis stage and decompensated cirrhosis, early posttransplant hazard and later survival benefit, and the risk of transplantation versus the risk of waiting. In that framework, screening is not merely classification, the waiting list is not merely a queue, and transplantation is not merely a procedure: each is a timed clinical decision shaped by competing forms of loss.